Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jun 11:11:236.
doi: 10.1186/1471-2407-11-236.

Cervical Mullerian adenosarcoma with heterologous sarcomatous overgrowth: a fourth case and review of literature

Affiliations
Review

Cervical Mullerian adenosarcoma with heterologous sarcomatous overgrowth: a fourth case and review of literature

Tito Silvio Patrelli et al. BMC Cancer. .

Abstract

Background: Uterine sarcomas are relatively rare tumors that account for approximately 1-3% of female genital tract malignancies and between 4-9% of uterine cancers. Less than 8% of all cases are Mullerian adenosarcoma, a distinctive uterine neoplasm characterized by a benign, but occasionally atypical, epithelial and a malignant, usually low-grade, stromal component, both of which should be integral and neoplastic constituents of the tumor. Mullerian adenosarcoma with sarcomatous overgrowth (MASO) is a very aggressive variant, associated with post-operative recurrence, metastases, even when diagnosed in early stage.

Case presentation: We present a fourth MASO case derived from uterine cervix in a 72-year-old woman with metrorrhagia and a polypoid mass protruding through the cervical ostium. Total abdominal hysterectomy, bilateral salpingo-oophorectomy, systematic pelvic lymph node dissection, omental biopsy and appendectomy were performed. Surgery treatment was associated with adjuvant whole-pelvis radiation (45 Gy) and adjuvant chemotherapy (cisplatin/ifosfamide). After nine months of follow up, the patient was free of tumor.

Conclusions: The rarity of MASO of the cervix involves a management difficult. Most authors recommend total abdominal hysterectomy, usually accompanied by bilateral salpingo-oophorectomy. There is no common agreement on staging by lymphadenectomy during primary surgery and adjuvant chemo-radio therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Microscopic features and immunohistochemistry. 1.1 rhabdoid cells, 1.2 rhabdoid cells with necrosis, 1.3 mesenchymal stomal cell differentiation, 1.4 vimentin immunohistochemistry, 1.5 desmin immunohistochemistry.

References

    1. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116(1):131–9. doi: 10.1016/j.ygyno.2009.09.023. - DOI - PubMed
    1. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004;93(1):204–8. doi: 10.1016/j.ygyno.2003.12.029. - DOI - PubMed
    1. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur J Cancer. 1997;33(6):907–11. doi: 10.1016/S0959-8049(97)00040-3. - DOI - PubMed
    1. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst. 1986;76(3):399–402. - PubMed
    1. Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 2009;104(3):177–8. doi: 10.1016/j.ijgo.2008.12.008. Erratum in: Int J Gynaecol Obstet. 2009 Sep;106(3):277. - DOI - PubMed

MeSH terms